Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From a Prospective, Open-Label Phase 2 Study
Accordingly, we anticipate that the many members of this drug class (including various dual- and tri-agonists) currently under development will continue to drive adverse effects disproportionately in women
We do not grant you any licenses, express or implied, to the intellectual property of SkinThera or our licensors except as expressly authorized by these Terms
PMID 15290671
We track outcomes using InBody body composition analysis , which measures skeletal muscle mass, body fat percentage, visceral fat level, phase angle (cellular health), segmental lean analysis, and basal metabolic rate at intake and at each follow-up
Controlled elimination of intracellular H(2)O(2): regulation of peroxiredoxin, catalase, and glutathione peroxidase via post-translational modification
